Drug Discovery World
JUNE 7, 2023
LC : As we describe in Nature Reviews Cancer (NRC), scientists have known since the 1970s that tumours were populated by immune cells; however, it took several years of pre-clinical studies to prove that macrophages were key players in tumour progression. DS: Congratulations on the publication of your discoveries in Nature Reviews Cancer.
Drug Discovery World
NOVEMBER 9, 2023
Gail Calvert, Field Application Scientist, Sartorius UK, on: ‘Leveraging integrated and advanced technologies for successful cell line development’. Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 13, 2023
Novel/alternative ML-enabled screening technologies for higher POS Following chairperson’s remarks from M Frank Erasmus, PhD, Head, Bioinformatics, Specifica, there will be four presentations and a panel discussion. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.
Drug Discovery World
NOVEMBER 8, 2023
Sebastian Jaeger, PhD, Senior Scientist, ADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA, on: ‘Evaluation of Fcab-drug conjugates as a novel antibody-based format for targeted drug delivery’.
Drug Discovery World
OCTOBER 17, 2022
For pharma and biotech companies – whether working on small or large molecule drugs, or cell and gene therapies – this means empowering scientists with better and faster data management approaches, best practices, and leading technologies so they can pinpoint new molecules and formulations and modify existing ones more easily and quickly.
Drug Discovery World
NOVEMBER 30, 2023
DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023. The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. GSK has developed high-throughput mammalian and E.
Drug Discovery World
NOVEMBER 15, 2022
Even as methods in DNA synthesis continue to advance, scientists’ reliance on third-party companies for synthesising DNA creates a bottleneck, impeding research timelines. . “If Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. .
Expert insights. Personalized for you.
52 
Let's personalize your content